| Market Cap | $6.99B+213.1% |
| Revenue (ttm) | $182.57M |
| Net Income | -$1.11B |
| EPS | -$1.06 |
| Shares Out | 1.06B |
| PE Ratio | n/a |
| Forward PE | -21.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,095,887 |
| Open | $6.72 |
| Previous Close | $6.70 |
| Day's Range | $6.41 - $6.83 |
| 52-Week Range | $1.95 - $12.43 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | $14.25(+116.89%) |
| Earnings Date | Nov 9, 2026 |
About IBRX
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating IBRX in the last 3 months, one vote each. Issuer-paid research is not counted.
$IBRX stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of IBRX by members of U.S. Congress
| Lisa McClainHouse / R | Purchase$1.00K – $15.00K | Sep 30, 2026 |
| Lisa McClainHouse / R | Purchase$1.00K – $15.00K | Sep 28, 2026 |
Recently reported changes in IBRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IBRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IBRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IBRX Revenue by Segment or Geography
| Product revenue, net | $48.74M | 99.79% |
| Other revenues | $104.00K | 0.21% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IBRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IBRX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from IBRX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Mixed coverage: Positive pipeline catalysts (Anktiva FDA filing, trial wins, institutional buying) offset by Q3 earnings miss, Anktiva sales decline, going-concern warning, and sharp stock declines.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| RVER | Trenchless Fund ETF | 4.72% |
| CNCR | Loncar Cancer Immunotherapy ETF | 3.28% |
| GERM | ETFMG Treatments, Testing and Advancements ETF | 3.14% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 2.20% |
| HYP | Golden Eagle Dynamic Hypergrowth ETF | 2.01% |
| BUZZ | VanEck Social Sentiment ETF | 1.98% |
| BBP | Virtus Biotech ETF | 1.21% |
| XBI | State Street SPDR S&P Biotech ETF | 0.72% |
| JSML | Janus Henderson Small Cap Growth Alpha ETF | 0.50% |
| CANC | Tema Oncology ETF | 0.49% |
| FNY | First Trust Mid Cap Growth AlphaDEX Fund | 0.48% |
| JSMD | Janus Henderson Small/Mid Cap Growth Alpha ETF | 0.45% |
Weight is the stock’s share of each fund’s holdings.
